Table 2.

Summary of the European expert consensus statement regarding genetic counselling, and testing of susceptibility genes for therapeutic decision-making in breast cancer [46]

1) High throughput sequencing technologies (i.e. NGS) are a sufficient testing method

2) Patients with familial history of breast cancer should not be restricted to only BRCA1/2 predictive

3) BRCA1/2, TP53 and PALB2 should all be included on a basic gene panel

4) Different populations may require different gene sets: PTEN, STK-11, ATM, CHEK2, CDH-1, MLH1, MSH2, MSH6, BRIP1, and RAD51D/C

5) 69% recommended that testing should be offered to all patients with breast cancer, and not restricted to advanced disease